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Abstract 
Although renal transplantation has proved a successful treatment for the patients with 
end-stage renal failure, the therapy is hampered by the problem of serious shortage of 
donor organs. Regenerative medicine using stem cells, including cell transplantation 
therapy, needs to be developed to solve the problem. We previously identified the 
multipotent progenitor cells in the embryonic mouse kidney that can give rise to several 
kinds of epithelial cells found in adult kidney, such as glomerular podocytes and renal 
tubular epithelia. Establishing the method to generate the progenitors from human 
pluripotent stem cells that have the capacity to indefinitely proliferate in vitro is 
required for the development of a kidney regeneration strategy. We review the current 
status of the research on the differentiation of pluripotent stem cells into renal lineages 
and describe cues to promote this research field.  
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An increasing number of patients with end-stage renal failure undergo dialysis therapy 
around the world. It causes both medical and medico economical problems. Renal 
transplantation has proved a successful therapy for most patients with end-stage renal 
failure, as the therapy results in a significant improvement in the patient’s quality of life, 
and prolongs survival. And it is also considered cost-effective [1]. However, the annual 
increase in the number of new patients with end-stage renal disease who need a renal 
transplant and the widening gap between the demand for and the supply of donor kidney, 
has led to a progressive shortage of donor organs for transplant around the world. This 
has become a serious issue and is even worsened by limited graft survival due to 
immune rejection [1].  
Among strategies to overcome these problems is kidney regeneration using 
stem cells. Stem cells contain two large categories; organ-specific or somatic stem cells 
and pluripotent stem cells. In contrast to organ-specific stem cells that generally have 
the limited potential for growth and differentiation, pluripotent stem cells, such as 
embryonic stem (ES) cells [2-4] and induced pluripotent stem (iPS) cells [5-7], have a 
virtually unlimited replicative capacity on culture dishes and are theoretically able to 
give rise to any cell types in the body. The cell types have increasingly been used as a 
model system for understanding developmental mechanisms. In addition, in vitro 
culture and the differentiation of the stem cells offer unique opportunities for disease 
modeling, drug discovery, toxicology and cell replacement therapy [8]. The generation 
of specific functional cell types from ES cells has been demonstrated, including neuron, 
vascular endothelia, cardiomyocytes, hematopoietic cells, pancreatic insulin-producing 
cells, and hepatocyte-like cells [9]. However, the protocol for in vitro differentiation of 
pluripotent stem cells into renal lineage cells has not been fully established.  
Other approaches to regenerate kidney have also been investigated using 
organ-specific local stem cells within the kidney and bone marrow-derived 
hematopoietic stem cells [10]. Kidney regeneration using mesenchymal stem cells 
localized in bone marrow has also been investigated [11].  
This review first summarizes the mechanisms of kidney development, then 
focuses on the directed differentiation of pluripotent stem cells into renal lineages based 
on the knowledge of kidney development, and finally describes potential applications of 
this strategy for various research fields. In vitro generation of kidney using the 
undifferentiated cell mass in amphibian eggs, similar to mammalian pluripotent stem 
cells in that the cell mass can differentiate into various organs in vitro, is also described 
as references to kidney regeneration in mammals.  
Mechanisms of kidney development 
Vertebrates develop successively three kidneys; pronephros, mesonephros and 
metanephros. The three kidneys consist of a basic functional unit, the nephron, although 
the number of nephron differs among the kidneys [12]. The kidneys are derived from a 
portion of the early embryonic germ layer, intermediate mesoderm that is located 
between lateral and paraxial mesoderms [13]. Lineage tracing experiments have 
recently demonstrated that intermediate mesodermal cells expressing Odd-skipped 
related (Osr) -1, an essential transcriptional factor for intermediate mesoderm and 
kidney development, give rise to all components consisting of mammalian adult kidney 
metanephros [13]. Metanephros is formed by reciprocal interaction between two tissues 
derived from intermediate mesoderm - metanephric mesenchyme and ureteric bud [12]. 
The ureteric bud induces the metanephric mesenchyme to differentiate into the epithelia 
of glomeruli and renal tubules. By creating a novel culture system which uses the 
co-culture with the cell line expressing a renal-epithelializing factor Wnt4, we 
previously demonstrated that mouse metanephric mesenchyme contains multipotent 
progenitor cells that can give rise to several kinds of epithelial cells found in adult 
kidney, such as glomerular podocytes and epithelia of proximal and distal renal tubules 
and Henle’s loop [14] (Figure 1A, B). The progenitor cells are contained only in the cell 
population strongly expressing Sall1, a zinc finger transcriptional factor that is essential 
for kidney development. It was also shown that these progenitor cells can reconstitute a 
three dimensional kidney structure in vitro, which contains glomeruli- and tubule-like 
components in an organ culture setting (Figure 1C, D). The presence of the progenitor 
cells was also demonstrated in vivo by using a lineage tracing experiment for Six2, 
which is also an essential transcriptional factor for kidney development [15].  
The progenitors in metanephric mesenchyme differentiate into epithelia after 
Wnt stimulation, but a cell fate decision is required for further differentiation toward 
glomerular podocytes, proximal or distal renal tubules, or Henle’s loop. Molecular 
mechanisms of the cell fate decision is largely unknown, although it was demonstrated 
that Notch2 is required for the differentiation of proximal nephron structures, such as 
podocytes and proximal renal tubules, as Notch2 deletion leads to the impaired 
formation of these proximal structures [16]. There may be many other molecules 
involved in the lineage commitment, and they remain to be elucidated. Metanephric 
mesenchyme may well contain at least two other progenitor populations in addition to 
the epithelial progenitors; 1) vascular progenitor cells that can give rise to vascular and 
glomerular endothelial cells, vascular smooth muscle cells (pericytes) and mesangial 
cells, and 2) stromal progenitors eventually developing into interstitial cells within adult 
kidney. The ureteric bud is known to elaborate the lower urinary tract system - from 
collecting ducts through renal pelvis and ureters to a part of the urinary bladder [12]. 
Most of the mechanisms of the lineage commitment, by which the intermediate 
mesoderm gives rise to ureteric bud, stromal and vascular cells, are unknown. Further 
examinations will be required to elucidate the mechanisms, which will eventually help 
us completely understand the commitment of multiple cell lineages within a kidney and 
in reproduce it in vitro from pluripotent stem cells.       
Animal cap in fertilized eggs of amphibians 
Amphibians have been used as experimental animals for the research of developmental 
biology mainly because of its easiness to handle and observe. In amphibian eggs, the 
ectodermal cell mass of mid-blastula embryos, called animal cap, is similar to ES and 
iPS cells in mammals in that it has a potential of multipotent differentiation. The animal 
cap can be easily excised from fertilized eggs and cultured as explants in vitro in simple 
saline solution. After the treatment with differentiation-inducing factors, animal cap can 
differentiate into various tissues and organs in vitro [17]. The pronephros is a simple 
excretory organ of Xenopus larvae with only one nephron, consisting of glomus, a 
filtering unit equivalent to glomerulus in metanephros, tubule and duct. When animal 
caps are treated with the combination of activin A, a protein inducer belonging to 
transforming growth factor (TGF) -  supperfamily, and retinoic acid, the differentiation 
into pronephric tubules was observed [18]. In the same differentiation system, the 
marker gene expression for pronephric glomus was detected [19]. We demonstrated that 
pronephric duct, a third component of pronephric kidney, can be generated in the 
explants, in addition to pronephric tubule and glomus, and that the pronephros formed 
in vitro is similar to that in Xenopus embryos both histologically and in gene expression 
(Figure 2) [20]. The pronephic tubule and duct also have the similar ultrastructure to 
those of Xenopus embryos by the examination with electron microscopy.    
The pronephros formed from animal cap in vitro shows temporarily a similar 
gene expression pattern to that in Xenopus embryos. Using the in vitro system to 
generate pronephric tissue, the molecular mechanisms underlying pronephros 
development has been investigated and some molecules involved in the formation of 
pronephros were identified [17]. Although the pronephros produced in vitro from 
animal cap cannot be directly translated to clinical application, this system should 
facilitate the study of kidney regeneration and may promote a shift from tissue 
engineering to clinical applications. Indeed, this induction method established for 
animal cap using activin A and retinoic acid has been applied for a differentiation 
experiment from mouse ES cells into renal lineages [21]. 
ES cells 
ES cells are pluripotent stem cells derived from the inner cell mass of fertilized eggs in 
mammals. The first derivation of mouse ES cells by Evans and Martin was described in 
1981 [2, 3] and human ES cells was established in about 20 years later [4]. Both mouse 
and human ES cells have a virtually unlimited replicative capacity and are theoretically 
able to give rise to any cell types in the body. Since its derivation, mouse ES cells have 
mainly been used as a research tool to generate experimental mouse models by the 
combination with gene targeting techniques. However, after the success in human ES 
cell derivation, regenerative medicine strategy has been considered closer to clinical 
applications, which aim at accomplishing the functional recovery of dysfunctional 
organs by transplanting organ-specific cell types generated from ES cells in vitro. The 
research on the in vitro differentiation of ES cells into specific cell types of various 
organs has since been more vigorously investigated to develop cell transplantation 
therapies. 
In vivo injection of ES cells into immunocompromized mice can produce 
teratoma, which are tumors containing cells of all three embryonic germ layers 
(ectoderm, mesoderm and endoderm). It was shown that glomerulus- and tubule-like 
structures can be formed in teratomas derived from mouse [22] and human ES cells [4], 
which demonstrate that ES cells do have a potential to differentiate into kidney lineages. 
Furthermore, fundamental research aiming to establish the methods to efficiently induce 
mouse ES cells into renal progenitors and fully differentiated renal cells has already 
been carried out [21, 23-26]. Mouse ES cells treated with the combination of hepatocyte 
growth factor (HGF) and activin A in addition to the transfection of renal-epithelializing 
factor Wnt4 [23], the combination of activin A, Bone morphogenetic protein (BMP)-7 
and retinoic acid [21], activin A alone [24], BMP-4 alone [25], or the combination of 
four chemical compounds [26], produced cells expressing markers for intermediate 
mesoderm, developing kidney and fully differentiated renal cells. In some reports, the 
induced cells formed tubule-like structures in or were incorporated into developing 
mouse kidneys [21, 23, 24]. Few reports have described the directed differentiation of 
human ES cells into renal lineage. It was shown that human ES cells differentiated in 
vitro into cells expressing WT1 and rennin, marker genes for glomeruli, following the 
treatment with growth factors [27]. Recently it has been reported that the combinational 
treatment with activin A, retinoic acid, and BMP-4 or BMP-7 also induces marker gene 
expression for intermediate mesoderm and developing kidney from human ES cells 
[28].   
In summary, these data suggest that ES cells are a potential source for kidney 
regeneration, although the efficiency or the induction rate of generation of renal cells 
from ES cells is unknown in many cases. It remains to be determined whether kidney 
lineage cells produced from ES cells have a function as kidney. It is also unknown 
whether tubule-like structures or cells integrated into kidney are metanephric or of 
earlier kidneys (pronephros and mesonephros). The research on kidney regeneration 
using ES cells is at its beginning, and further examinations are needed to develop this 
research field. 
iPS cells 
One of the more remarkable observations in the past century is that the differentiation is 
not a unidirectional process. Instead, we can turn back the clock on differentiated cells. 
This rewinding of the developmental clock is termed nuclear reprogramming and is 
often defined as the process whereby an adult somatic nucleus has developmental 
potential restored to it. There are two conventional ways that nuclear reprogramming 
could be accomplished: somatic cell nuclear transfer or cloning and cell fusion [29]. 
Somatic cell nuclear transfer (SCNT), a procedure in which the nucleus of an adult cell 
is injected into an unfertilized egg whose chromosomes have been removed, has 
demonstrated that the genome of adult cells can be reset to an embryonic state. Using 
this strategy researchers have generated cloned embryos that possess the potential to 
develop into an adult animal or become an ES cell line that is genetically identical to 
that of the donor nucleus. These experiments demonstrated that no irreversible changes 
are made to the genome during development and further showed that animal oocytes 
harbored factors that could accomplish nuclear reprogramming. In a related series of 
experiments, a number of researchers have shown that when somatic cells are fused 
with ES cells, the resulting tetraploid hybrid cells silence the expression of somatic 
genes and establish a program of transcription indistinguishable from ES cells, 
indicating that ES cells contain the necessary reprogramming activities to accomplish 
this transformation. Thus, the cytoplasm of the enucleated oocyte and the ES cell is able 
to re-establish the pluripotent state via a mechanism dependent on global epigenetic and 
transcriptional changes. The mechanism by which this transformation from adult 
somatic cells to pluripotent stem cells occurred and the mediators of nuclear 
reprogramming was largely undefined.  
In a breakthrough experiment, Takahashi and Yamanaka identified four factors 
normally found in ES cells - Oct3/4, Sox2, c-Myc, and Klf4 - and reported that they 
were sufficient to reprogram both mouse and human somatic cells to closely resemble 
mouse and human ES cells [5-7]. They called the cell type induced pluripotent stem 
(iPS) cells. Since the reports, the technique has been rapidly confirmed, improved and 
subsequently applied to successfully reprogram somatic cells.  
Therapeutic approaches using human ES cells face the two major problems. 
One is the ethical issue derived from the usage of human fertilized eggs, and the other is 
immune rejection in any cell or tissue transplantation due to histocompatibility antigenic 
differences between ES cells and patients. These problems have become resolvable by 
using iPS cells, which can be generated from somatic cells of patients. In the next step 
after iPS cell derivation, significant progress has been made in re-differentiating iPS 
cells into somatic cells including active motor neurons [30], insulin-secreting islet-like 
clusters [31], and a number of cardiovascular cells (arterial endothelium, venous 
endothelium, lymphatic endothelium, cardiomyocytes) [32, 33]. To date, few reports 
have described the generation of renal lineage cells from iPS cells. However, the 
phenotype of iPS cells is indistinguishable from ES cells and accumulated experiences 
and knowledge using ES cells to generate mesodermal and renal lineage cells are 
potentially applicable to iPS cell differentiation culture.  
The iPS cell technology enables the creation of patient-specific pluripotent cell 
lines that carry disease genotypes. The generation of disease-specific iPS lines has been 
first reported from a familial form of a neurodegenerative disorder, amyotrophic lateral 
sclerosis (ALS) [34]. Disease-specific iPS cells has also been produced by other groups 
from more than 10 different genetic diseases, including Parkinson’s disease, type-1 
diabetes, Duchenne’s and Becker’s muscular dystrophy, adenosine deaminase 
deficiency-related severe combined immunodeficiency, Shwachman-Bodian-Diamond 
syndrome, Gaucher disease type III, Huntington’s disease, Down’s syndrome, and the 
carrier state of Lesch-Nyhan syndrome [35]. These cell lines could be used both as in 
vitro models for the study of disease and as potential sources of material for cell 
replacement therapy. Ultimately, a greater understanding of the process by which 
cellular identity is shaped and altered may allow for the generation of particular cell 
types for the treatment of degenerative diseases. These approaches can be also applied 
to genetic renal diseases. 
Other clinical applications using ES or iPS cell technology include the usage of 
stem cell-derived tissues for in vitro toxicology screening. For example, it has been 
shown that human ES or iPS cell-derived cardiomyocytes can be used to examine toxic 
effects of drug compounds on caridomyocytes, such as drug-induced QT interval 
prolongation that can lead to sudden cardiac death and is a major safety concern for the 
drug industry [36]. The similar approaches may well be the use of ES or iPS 
cell-derived hepatocytes and renal cells in testing hepatotoxicity and nephrotoxicity of 
drug compounds. 
Cues to develop kidney regeneration strategy from pluripotent stem cells 
By mimicking signals used in embryonic development, to the extent that they are 
known, a stepwise protocol was explored to differentiate ES or iPS cells into some 
specific cell types in adult organs, such as pancreas and liver [37, 38]. For the 
generation of insulin-producing cells in pancreas, ES cells has been first differentiated 
into definitive endoderm, then foregut endoderm, followed by pancreatic progenitors, 
and eventually insulin-expressing endocrine cells [37]. These stepwise approaches may 
be used in generating renal lineage cells from ES or iPS cells, and it should involve 
directing the pluripotent stem cells first to form intermediate mesoderm, then the renal 
progenitors, followed by the eventual formation of functional renal cells found in adult 
kidney. 
It has recently been shown that significant differences exist in the 
differentiation potential of different human ES cell lines, even though the observable 
differences in the pluripotent state are marginal [39]. Moreover, some human ES cell 
lines have a propensity to differentiate into certain lineages or cell types. These results 
also suggested that pluripotent stem cells derived by other means including iPS cells 
may well show a similar variability. The finding also underscores the importance of 
using suitable stem cell lines for the renal lineage differentiation.  
Directed differentiation of pluripotent stem cells into specific organ lineages is 
usually carried out through the combination of cell-cell interactions (co-culture with 
some cell lines), exposure to diffusible factors (growth factor) and other positional cues 
(extracellular matrix) that ultimately alter gene expression conferring a specific cellular 
identity and function. Direct genetic manipulations on stem cells using the 
overexpression of cDNA, small interfering RNA (siRNA) or short hairpin RNA 
(shRNA) has been also performed to generate specific cell types. It has been recently 
demonstrated that high-throughput screening of chemical compounds can be used to 
identify a small molecule that has a potential to induce the differentiation of pluripotent 
stem cells into specific lineages [40]. In the report, a chemical compound, (-) – 
indolactam V, known to activates protein kinase C (PKC) signaling, was shown to 
induces the differentiation of a substantial number of pancreatic progenitor cells from 
human ES cells. It was also shown that the activated PKC signal is involved in the 
pancreatic specification in human ES cell culture [40]. Similarly, chemical screens in an 
unbiased high-throughput method can be applied for the identification of chemical 
compounds to induce renal lineage differentiation from pluripotent stem cells and the 
elucidation of mechanisms of kidney differentiation. 
Conclusion 
Research for the kidney regeneration strategy using pluripotent stem cells is just at its 
beginning. Of course, continued efforts to elucidate the developmental mechanisms of 
mesoderm formation, the specification into kidney lineages, and nephron specification 
should be made. These investigations are necessary for the establishment of 
differentiation protocols from pluripotent stem cells into renal lineages. Further 
investigations using pluripotent stem cells as a model for kidney development will 
facilitate our understanding of kidney precursor specification and the development of 
new cell-based therapies for the treatment of renal diseases. Because of the annual 
increase in the number of patients with end-stage renal failure who have to undergo 
dialysis therapy around the world, regenerative medicine strategies using pluripotent 
stem cells needs to be developed. 
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Multipotent progenitor cells in metanephric kidney. (A) In vitro colony formation from 
a single progenitor cell within metanephric mesenchyme on feeder cells expressing 
Wnt4. (B) A single progenitor cell divides and differentiates into two renal lineages; 
(upper pannel) podocytes (red: peanut agglutinin; PNA) and proximal tubular epithelia 
(green: Lotus Tetragonobulus lectin; LTL), (lower) proximal (green: LTL) and distal 
tubular epithelia (red: E-cadherin, arrows). (C) Only cell population strongly expressing 
Sall1 (Sall1-GFP 
high
) that contains multipotent progenitors (upper panels) differentiate 
into kidney structure in organ culture, whereas that weakly expressing Sall1 (Sall1-GFP 
low
, lower) disappear. (D) Hematoxylin-eosin staining of sections of Sall1-GFP 
high
 
aggregates at day 10. Tubule- (t) and glomerulus-like structures (g) are seen. Bars: (A, 
B) 50 m, (C) 500 m, (D) 25 m. 
 
Fig. 2 
Pronephric kidney formed in vitro from undifferentiated cells in an amphibian. Double 
immunostaining of stage 42 equivalent explants (A, B) and a stage 40 Xenopus larvae 
(C, D) using pronephric tubule-specific antibody 3G8 (red) and pronephric duct-specific 
antibody 4A6 (blue). Whole-mount immunostaining patterns (A, C) and 
photomicrographs of sections (B, D) are shown. (A, B) Explants treated with activin A 
and retinoic acid contain both 3G8-positive (pronephric tubules, arrows) and 
4A6-positive tubular structures (pronephric ducts, arrowheads). Bars: 1 mm.  
 


